Table 1. Tumor Phenotype of Nf1 flox/flox; DhhCre mice.
The table summarizes the sex; strain background (note that the FVB/N deriving from the DhhCre allele was re-derived onto CD1 [see text for details]); age at sacrifice; tumor grade; age at time of partial paralysis; months from partial paralysis to sacrifice; reason for sacrifice; at autopsy, gross presence of plexiform GEM-neurofibroma; at autopsy, gross presence of dermal GEM-neurofibroma; at autopsy, gross presence of pigmentation; at autopsy, location of plexiform GEM-neurofibroma.
| A | B | C | D | E | F | G | H | I | J | K | L | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Age at | Tumor | Paralysis first | Months to | Plexiform | Dermal | Plexiform neurofibroma | |||||
| 2 | ID# | Sex | Background | sacrifice | Grade | appears, months | sacrifice | Reason for Sacrifice | Neurofibromas | Neurofibromas | Pigmentation | location |
| 3 | NFC407 | F | 129/BL 6/FVBN | 9.2 | I* | 7.1 | 2.1 | paralysis | Y | N | N | Cervical |
| 4 | NFC412 | F | 129/BL 6/FVBN | 7.6 | I* | 4.8 | 2.8 | paralysis | Y | Y | N | Cervical |
| 5 | NFC421 | M | 129/BL 6/FVBN | 11.0 | I | 8.1 | 2.9 | paralysis+ dermatitis | Y | N | Y | Cervical |
| 6 | NFC422 | F | 129/BL 6/FVBN | 10.8 | I* | 8.2 | 2.6 | paralysis | Y | Y | Y | Cervical, thoracic |
| 7 | NFC423 | M | 129/BL 6/FVBN | 7.6 | I | 5.5 | 2.1 | found dead | Y | N | N | Cervical, thoracic |
| 8 | NFC425 | F | 129/BL 6/FVBN | 5.6 | I | 5.1 | 0.5 | paralysis | Y | Y | Y | Cervical, thoracic |
| 9 | NFC426 | M | 129/BL 6/FVBN | 11.0 | I | 7.1 | 3.9 | paralysis+ dermatitis | Y | Y | N | Cervical, thoracic |
| 10 | NFC430 | M | 129/BL 6/FVBN | 7.4 | I/II* | 4.7 | 2.7 | paralysis | Y | Y | Y | Cervical |
| 11 | NFC434 | F | 129/BL 6/FVBN | 8.2 | I* | 6.1 | 2.1 | paralysis | Y | N | N | Cervical, thoracic |
| 12 | NFC436 | F | 129/BL 6/FVBN | 9.2 | I* | 8.1 | 1.1 | paralysis | Y | N | N | Cervical, thoracic |
| 13 | NFC443 | F | 129/BL 6/FVBN | 9.2 | I | 7.7 | 1.5 | paralysis | Y | N | N | Thoracic |
| 14 | NFC446 | F | 129/BL 6/FVBN | 7.8 | I | 7.0 | 0.8 | paralysis | Y | N | N | Cervical, thoracic |
| 15 | NFC450 | M | 129/BL 6/FVBN | 9.4 | I | 7.0 | 2.4 | paralysis | Y | N | N | Cervical, thoracic, lumbar |
| 16 | NFC454 | F | 129/BL 6/FVBN | 7.8 | I | 6.2 | 1.6 | paralysis | Y | N | Y | Cervical, cauda equina |
| 17 | NFC459 | M | 129/BL 6/FVBN | 8.4 | I | 7.2 | 1.2 | paralysis | Y | N | N | Cervical |
| 18 | NFC470 | F | 129/BL 6/FVBN | 12.5 | I* | 10.6 | 1.9 | paralysis + abdominal tumor | Y | Y | N | Cervical, thoracic |
| 19 | NFC473 | M | 129/BL 6/FVBN | 5.4 | I* | 5.3 | 0.1 | paralysis | Y | Y | Y | Cervical, thoracic, cauda equina |
| 20 | NFC477 | M | 129/BL 6/FVBN | 9.8 | I* | 8.1 | 1.7 | paralysis | Y | N | N | Cervical, thoracic |
| 21 | NFC478 | F | 129/BL 6/FVBN | 8.2 | I | 6.7 | 1.5 | paralysis | Y | N | Y | Cervical, lumbar |
| 22 | NFC493 | M | 129/BL 6/FVBN | 12.5 | I | 11.0 | 1.5 | paralysis | Y | Y | Y | Cervical |
| 23 | NFC495 | F | 129/BL 6/FVBN | 7.1 | I* | 5.3 | 1.8 | paralysis | Y | N | N | Cervical, thoracic |
| 24 | NFC502 | M | 129/BL 6/FVBN | 12.6 | I* | 10.0 | 2.6 | paralysis | Y | Y | Y | Cervical, thoracic (also liver lymphoma) |
| 25 | NFC512 | M | 129/BL 6/FVBN | 11.3 | I* | 8.0 | 3.3 | paralysis+ dermatitis | Y | Y | N | Cervical |
| 26 | NFC516 | M | 129/BL 6/FVBN | 8.9 | I | 8.7 | 0.2 | paralysis+ dermatitis | Y | Y | N | Cervical |
| 27 | NFC519 | M | 129/BL 6/FVBN | 9.7 | I | 5.5 | 4.2 | lethargy + paralysis | Y | N | N | Cervical, thoracic |
| 28 | NFC528 | M | 129/BL 6/FVBN | 6.9 | I* | 5.5 | 1.4 | paralysis | Y | Y | Y | Cervical, thoracic |
| 29 | NFC534 | M | 129/BL 6/FVBN | 11.8 | I | 11.0 | 0.8 | skin ulcer + dermatitis | Y | Y | N | Cervical, thoracic |
| 30 | NFC536 | M | 129/BL 6/FVBN | 7.6 | I | 6.1 | 1.5 | paralysis | Y | N | Y | Cervical, thoracic |
Y = yes; N= no.
*
denotes S100β stain. All cases analyzed for S100β stain were positive for S100β staining.